Isoniazida Labesfal

Isoniazid, the active ingredient in Isoniazida Labesfal, is an antitubercular agent presented as an oral dosage form for oral use. It is employed in the treatment of active tuberculosis and in the prevention of latent tuberculosis infection in at‑risk individuals.

GNH USA supplies Isoniazida Labesfal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured products that meet EU regulatory standards and facilitating reliable access across multiple regions.

Isoniazid is used in antitubercular therapy to target Mycobacterium tuberculosis infection. - Active tuberculosis: eradicates replicating Mycobacterium tuberculosis, contributing to cure of pulmonary and extrapulmonary disease. - Latent tuberculosis infection: reduces risk of progression to active disease in individuals with positive tuberculin test or recent exposure. - Preventive therapy in high‑risk contacts: provides chemoprophylaxis for persons exposed to contagious TB cases.

Isoniazid may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Peripheral neuropathy: tingling or numbness in extremities. - Hepatotoxicity: transient elevation of liver enzymes. - Rash: mild skin irritation or itching.

Serious or Rare Side Effects: - Severe hepatitis: jaundice, abdominal pain, dark urine. - Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement. - Anaphylaxis: acute allergic reaction with airway compromise.

Before initiating therapy, several precautions should be observed. - Liver function monitoring: assess baseline transaminases and repeat during therapy. - Vitamin B6 supplementation: consider pyridoxine to reduce neuropathy risk. - Alcohol consumption: avoid or limit alcohol due to increased hepatotoxicity risk. - Pregnancy and lactation: use only if benefits outweigh potential risks; consult healthcare provider. - Drug resistance: ensure susceptibility testing to prevent emergence of resistant Mycobacterium strains. - Store at ambient temperature: keep below 25°C, retain in original container, protect from moisture and light.

Isoniazida Labesfal can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Rifampicin: reduces isoniazid plasma levels, compromising efficacy. - Anticonvulsants (e.g., phenytoin, carbamazepine): increase hepatic metabolism, lowering drug exposure. - Alcohol: synergistic hepatotoxic effect, heightening liver injury risk.

Moderate Interactions (Monitor Closely): - Acetylhydrazine‑containing drugs: may increase risk of hepatotoxicity. - Sulfonamides: potential additive liver toxicity. - Warfarin: may alter INR, requiring closer coagulation monitoring.